Resources

PET modality is one of the most rapidly growing area of medical imaging thanks to the availability of innumerous clinical centers with their own cyclotrons. To be able to cover the growing clinical demands, radiopharmacies are developing new tracers while keeping up their routine production in a (c)GMP environment.  In this symposium, Dr. Ida Nymann Petersen, PhD. and Dr. Vasko Kramer, PhD.will share their experience in the development of new tracers on the Synthera® Platform.  When?  May 20th 4-5pm CET (Central European Time)   REGISTER What will you learn ?   Synthesis of [18F]mFBG and [18F]FE-PE2I on Synthera®+ platform By Dr. Ida Nymann Petersen, PhD., Radiochemist at Rigshospitalet in Copenhagen, Denmark.   In this talk, the fully automated labelling of [18F]mFBG and [18F]FE-PE2I on the Synthera®+ and Synthera®+ HPLC platform will be presented. [18F]FE-PE2I was synthesized in 32 % RCY, 98 % RCP in 40 min. [18F]mFBG is currently under optimization.    Development of new tracers: from neurology to oncology applications. By Dr. Vasko Kramer, PhD., Head of Research & Development at Positron Pharma in Santiago, Chile.  He will present some of their results for the production and development of new, innovative PET imaging agents for neurological ([18F]F-PR04.MZ, [18F]F-Florbetaben, [18F]F-PI-2620), oncological ([18F]FAPi-74, [18F]F-AlF-NOTA-Octreotide), and research applications (7-[18F]F-Fluoro-tryptophan, 18F-Tetrazines) using a compact, cassette-based synthesis platform.     You can join this symposium even if you don’t attend eSRS meeting.

This year, IBA celebrates its 35th anniversary. 35 years of an incredible journey that began in the 1980s and that would change the lives of thousands of cancer patients. And mine too, of course! Because believe me, if the engineer I was at the time had been able to see all that has been achieved to date, he would never have believed it! And by the way, in terms of groundbreaking technology, there is a lot more to come soon! But that’s another story… For now, let’s go back to this journey and how it all started when I designed the first IBA Cyclotron : the Cyclone. My objective was to increase cyclotrons energetic efficiency by a factor 15: three times less electrical consumption for five times more beam power. Something nobody believed would be possible at the time! But the first prototype was a great success which led to the birth of Ion Beam Applications: IBA, allowing us to make the diagnosis of cancer and other critical diseases accessible for many patients around the world through PET and SPECT imaging. While also pioneering the advancement of protontherapy with 100.000 patients treated worldwide to this day. You could say that saving people’s life is my life’s work. Something we’re particularly proud of here at IBA ! Yet, we are not surgeons. Nor doctors. But we are here for the patients. They do not see us, but we do. Since more than 35 years. But the birthdays that really matter are those of people who were saved by IBA’s technology. Birthdays they can continue to celebrate. Because we know that every year that is taken away from the disease counts for three. So, long life to all cancer patients and long life to IBA! But our innovation story doesn’t stop here. We are beaming proud to announce the arrival of a new cyclone, fresh from our Beam Factory! The culmination of 35 years of experience and groundbreaking research. Get ready to be amazed… Yves Jongen, IBA Founder

Two IBA Rhodotron®TT 300-HE (High Energy) electron beam accelerators were rigged in Beloit, Wisconsin. The accelerators are critical components in a first-of-its-kind commercial-scale process to produce Mo-99, the parent radioisotope of technetium-99m, the most widely used medical imaging radioisotope, informing healthcare decisions for approximately 40,000 U.S. patients daily. We are proud to be part of this project !

Ever since IBA launched its first cyclotron in 1986, we have been on a mission to innovate and push the boundaries of technology further. Our goal? Offer you the best technology and services, while ensuring a high return on investment and low cost of ownership. We are pleased to invite you to a breakthrough announcement that’s a significant jump into the future. We’ll be holding an online event and will be honoured if you would attend.  When? June 10th 2021 at 3.00 pm CET  Register